HRMY - Harmony Biosciences Holdings, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$44.00
DETAILS
HIGH:
$50.00
LOW:
$36.00
MEDIAN:
$46.00
CONSENSUS:
$44.00
UPSIDE:
19.44%
About Harmony Biosciences Holdings, Inc. (https://www.harmonybiosciences.com)
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Jeffrey Dayno | President, Chief Executive Officer & Director | 1957 | $1,324,015 USD |
| Adam Zaeske | Executive Vice President & Chief Commercial Officer | 1973 | $946,228 USD |
| Kumar Budur | Executive Vice President and Chief Medical & Scientific Officer | 1971 | $919,062 USD |
| Andrew Serafin | Executive Vice President & Chief Strategy Officer | 1975 | $681,398 USD |
| Jeffrey S. Aronin | Founder & Non-Executive Chairman | 1968 | $77,500 USD |
| Peter Anastasiou | Chief Operating Officer | 1970 | $58,250 USD |
| Brennan Doyle | Vice President & Head of Investor Relations | – | – |
| Christian Ulrich | Executive VP, General Counsel & Corporate Secretary | – | – |
| Glenn Reicin | Chief Financial Officer | 1965 | – |
| Tricia Glover | Chief Compliance Officer | – | – |